预混门冬胰岛素30和预混人胰岛素30R治疗2型糖尿病疗效比较

A comparative study of premixed insulin aspart

目的比较预混门冬胰岛素30和预混人胰岛素30R疗效及安全性。方法采用每天2次的注射方案,选取口服药控制不佳的2型糖尿病患者48例,随机分为预混门冬胰岛素30治疗组和预混人胰岛素30R治疗组进行12周的比较,观察2种不同治疗方案对2型糖尿病患者糖化血红蛋白、4个时点的血糖(空腹及3餐后2 h)、低血糖发生的治疗结果。结果预混门冬胰岛素30治疗组的糖化血红蛋白(HbAlc)明显低于预混人胰岛素30R治疗组,预混门冬胰岛素30治疗组早餐、晚餐后2 h及空腹血糖低于预混人胰岛素30R治疗组,中餐后2 h血糖与预混人胰岛素30R治疗组相似,预混门冬胰岛素30治疗组低血糖发生率低于预混人胰岛素30R治疗组。结论预混门冬胰岛素30在疗效及安全性更优于预混人胰岛素30R。

Objective To compare the safety and efficacy of pemixed insulin aspart 30 with premixed human insulin 30R used in patients with type 2 diabetes. Methods 48 patients with type 2 diabetes using insulin twice a day were randomized into a premixed insulin aspart 30 group and a premixed human insulin 30R group. A 12-week study was conducted to compare safety and efficacy in the two groups in terms of changes of HbAlc, blood glucose at various points of a day and frequency of hypoglycemia. Results Premixed insulin aspart 30 group was associated with a significantly lower HbAlc than premixed human insulin 30R group. The former manifested lower blood glucose after breakfast, after dinner and before meals than the latter. No significant difference was observed after lunch. The incidence of major hypoglycemic episodes was lower in the premixed insulin aspart 30 group. Conclusion Premixed insulin aspart 30 is more effetive and safer than premixed human insulin 30R.